Killer Rash (Purpura Fulminans)
What is Killer rash (purpura fulminans)?
Purpura fulminans (PF) is a rare, life‑threatening dermatologic emergency characterized by the sudden appearance of extensive, painful skin bruising (purpura) that rapidly progresses to necrosis and gangrene. The term “killer rash” is sometimes used in lay language because the skin lesions can spread extremely quickly—often within hours—leading to multi‑organ dysfunction, disseminated intravascular coagulation (DIC), and a high mortality rate if not treated promptly.
PF is not a disease itself; it is a severe manifestation of an underlying problem that leads to uncontrolled clotting in small blood vessels of the skin and, in many cases, other organs. The hallmark is a striking purpuric patch that is non‑blanching (does not turn white when pressed), often with a central area of black eschar (dead tissue). The lesions are usually symmetric and may affect the extremities, trunk, and sometimes the face.
Because PF develops rapidly and can be the first sign of a catastrophic infection or coagulation disorder, recognizing it early is crucial. The condition is described in peer‑reviewed literature and guidelines from the Mayo Clinic, the CDC, and the World Health Organization.1,2
Common Causes
The most frequent precipitants of purpura fulminans can be grouped into infectious, genetic, and acquired coagulopathies. Below are 9 of the most common triggers:
- Neisseria meningitidis infection (meningococcemia) – the classic bacterial cause.
- Streptococcus pneumoniae or Staphylococcus aureus sepsis.
- Viral infections – especially varicella (chickenpox) in children and, rarely, influenza.
- Protein C deficiency – hereditary (autosomal recessive) or acquired (e.g., vitamin K antagonist therapy).
- Protein S deficiency – inherited or secondary to liver disease.
- Antiphospholipid syndrome – autoimmune hypercoagulable state.
- Disseminated intravascular coagulation (DIC) from severe trauma, burns, or malignancy.
- Warfarin‑induced skin necrosis – occurs when protein C levels fall faster than clotting factors.
- Hemolytic‑uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP) – microangiopathic disorders that can mimic PF.
Associated Symptoms
Purpura fulminans rarely occurs in isolation. The skin findings are usually accompanied by systemic signs of severe illness:
- Fever, chills, and rigors – especially with bacterial sepsis.
- Rapid heart rate (tachycardia) and low blood pressure (hypotension) indicating septic shock.
- Altered mental status – confusion, lethargy, or coma.
- Shortness of breath or respiratory distress.
- Abdominal pain, nausea, or vomiting.
- Decreased urine output (oliguria) suggesting kidney involvement.
- Laboratory evidence of DIC: low platelets, prolonged PT/PTT, low fibrinogen, and elevated D‑dimer.
- Elevated inflammatory markers (CRP, procalcitonin) and evidence of organ dysfunction on blood tests.
When to See a Doctor
Purpura fulminans demands immediate medical attention. Seek care if you notice any of the following:
- Sudden appearance of large, dark purple or black spots that do not fade with pressure.
- Rapid spreading of the rash—especially if it enlarges by more than 1 cm in a few hours.
- Severe pain at the site of the rash, out of proportion to any apparent injury.
- Signs of infection such as high fever (>38.5 °C/101.3 °F), chills, or a sick‑looking appearance.
- Bleeding tendencies (nosebleeds, gum bleeding, easy bruising) alongside the rash.
- Any combination of rash + low blood pressure, rapid breathing, confusion, or reduced urine output.
Because PF can progress to life‑threatening shock within hours, do not wait for the rash to “improve.” Call emergency services (911 in the United States) right away.
Diagnosis
Evaluation combines a rapid clinical assessment with targeted laboratory and imaging studies.
Clinical Assessment
- Full skin examination – documenting size, distribution, and evolution of purpuric lesions.
- Vital signs and assessment for sepsis criteria (fever, tachycardia, hypotension, altered mental status).
- History of recent infection, vaccinations, medication changes, or known clotting disorders.
Laboratory Tests
- Complete blood count (CBC) – often shows thrombocytopenia.
- Coagulation panel – PT, aPTT, fibrinogen, D‑dimer; typical DIC pattern is prolonged PT/aPTT, low fibrinogen, high D‑dimer.
- Serum chemistries – to assess kidney and liver function.
- Blood cultures – drawn before antibiotics to identify bacterial pathogens.
- Specific tests for protein C, protein S, antithrombin III levels; factor V Leiden or prothrombin G20210A mutation screening if hereditary cause suspected.
- Serology or PCR for Neisseria meningitidis, Streptococcus pneumoniae, varicella‑zoster, and other pathogens.
- Autoimmune work‑up – antiphospholipid antibodies, ANA, complement levels when indicated.
Imaging
- Chest X‑ray or CT to look for pneumonia or septic emboli.
- Ultrasound/Doppler of affected limbs to assess for arterial or venous thrombosis.
- CT or MRI of the brain if neurologic symptoms develop.
Skin Biopsy
In uncertain cases, a punch biopsy of an early lesion can show occlusion of dermal vessels with fibrin thrombi, supporting the diagnosis of PF. Histology also helps exclude vasculitis or other dermatologic mimickers.
Treatment Options
Management must be multidisciplinary—critical care, infectious disease, hematology, and surgery—and is aimed at four goals: eradicate the underlying trigger, interrupt the coagulopathy, support organ function, and minimize tissue loss.
Immediate Emergency Care
- Airway, Breathing, Circulation (ABCs) – initiate supplemental oxygen, IV fluid resuscitation, and vasopressors if hypotension persists.
- Broad‑spectrum antibiotics within the first hour of presentation. Empiric regimens often include a third‑generation cephalosporin (e.g., ceftriaxone) plus vancomycin; add meningococcal‑specific coverage (e.g., cefotaxime) if meningitis/meningococcemia is suspected.
- For viral triggers, acyclovir (for varicella) or appropriate antivirals are started.
Correction of Coagulopathy
- Protein C concentrate (available in many tertiary centers) – dose 100–150 IU/kg bolus, then 50–100 IU/kg every 6 hours; shown to improve survival in meningococcal PF.3
- Fresh frozen plasma (FFP) – provides clotting factors and protein C when specific concentrate is unavailable.
- Heparin (low‑dose intravenous) – may be used once bleeding is controlled, particularly in cases driven by ongoing thrombosis rather than DIC.
- Reversal of warfarin (if applicable) with vitamin K and FFP or prothrombin complex concentrates.
Supportive Organ Care
- Mechanical ventilation for respiratory failure.
- Renal replacement therapy (hemodialysis) if acute kidney injury develops.
- Blood transfusions – packed RBCs for anemia, platelets for severe thrombocytopenia.
- Vasopressor agents (norepinephrine, epinephrine) for refractory shock.
Surgical Intervention
- Early debridement of necrotic tissue to prevent secondary infection.
- Consideration of fasciotomies if compartment syndrome develops.
- Skin grafting or reconstructive surgery after the acute phase, once infection is cleared and coagulation stabilizes.
Home and Follow‑up Care
- Complete the full course of prescribed antibiotics (usually 2–4 weeks).
- Vaccination updates – especially meningococcal conjugate vaccine for survivors of meningococcal PF.
- Regular follow‑up with a hematologist to monitor protein C/S levels and assess for recurrent thrombosis.
- Physical therapy to maintain limb function after debridement.
- Wound care education – keep dressings clean, watch for signs of infection.
Prevention Tips
Because many cases are infection‑driven, prevention centers on reducing exposure to pathogens and managing underlying clotting disorders.
- Stay up‑to‑date with routine immunizations: meningococcal (A, C, W, Y, and B), pneumococcal, Hib, and varicella vaccines.
- Practice good hand hygiene and respiratory etiquette, especially during outbreaks of meningitis or influenza.
- Promptly treat bacterial skin infections, cellulitis, or abscesses to avoid systemic spread.
- If you have a known protein C or S deficiency, maintain regular hematology follow‑up and carry a medical alert indicating the condition.
- Avoid abrupt discontinuation of warfarin without physician guidance—use bridging protocols when surgery is needed.
- In newborns and infants, ensure prophylactic antibiotics are given when indicated (e.g., for maternal meningococcal colonization).
- Monitor for early signs of severe infection after travel to high‑risk areas; seek care promptly if fever develops.
Emergency Warning Signs
- Rapidly expanding purpuric or blackened skin lesions (especially on the limbs or trunk).
- Sudden drop in blood pressure or fainting.
- Severe, uncontrolled bleeding (gums, nose, or gastrointestinal).
- High fever (>39 °C / 102 °F) with chills and a “flu‑like” feeling.
- Confusion, seizures, or loss of consciousness.
- Shortness of breath or chest pain suggestive of pulmonary embolism or sepsis.
- Decreased urine output (<0.5 mL/kg/hr) or dark, tea‑colored urine.
If any of these occur, call emergency services (e.g., 911) or go to the nearest emergency department without delay.
Purpura fulminans is a medical emergency that can progress from a skin rash to multisystem organ failure in a matter of hours. Early recognition, aggressive antimicrobial therapy, and correction of the underlying coagulation disorder are critical for survival. If you or someone you care for develops a sudden, painful purple rash with systemic symptoms, seek emergency care immediately.
References:
- Mayo Clinic. Purpura fulminans. https://www.mayoclinic.org.
- Centers for Disease Control and Prevention. Meningococcal Disease. https://www.cdc.gov.
- Levy, J. H., et al. “Recombinant Human Activated Protein C in Severe Sepsis.” NEJM, 2001;345:699‑706.
- World Health Organization. Guidelines for the Management of Severe Bacterial Infections. 2023.
- Cleveland Clinic. Disseminated Intravascular Coagulation (DIC). https://my.clevelandclinic.org.